|Bid||8.71 x 900|
|Ask||9.29 x 800|
|Day's Range||8.27 - 8.83|
|52 Week Range||7.73 - 24.90|
|Beta (5Y Monthly)||1.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2022 - Aug 15, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.57|
Subscribe to Yahoo Finance Plus to view Fair Value for MGTX
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -42.86% and 39.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Phase 3 Lumeos Clinical Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Actively Dosing Patients- Phase 1 AQUAx Study of AAV-hAQP1 for Radiation-Induced Xerostomia Completed Dosing of Both Unilateral and Bilateral Cohorts in the First Quarter of 2022 LONDON and NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results fo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...